Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGRONOMICS LIMITED Net Asset Value 2013

Apr 9, 2013

7474_rns_2013-04-09_20a4ca4e-107f-47d4-81ef-44e7445b5ec8.html

Net Asset Value

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8542B

Port Erin Biopharma Investments Ltd

09 April 2013

Port Erin Biopharma Investments Limited ("The Company")

Net Asset Value calculation to 31st March 2013

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2013 was 11.22 pence per share, including un-invested cash of £287,310. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a considerable increase of 18.1% from the previous valuation of 9.50 pence per share, which included un-invested cash of £101,241. The revenue reserve has increased substantially to just over £1.0 million and represents a return of over 37.2% on investments after listing and operating costs."

Unaudited

to 31 March 2013

£
Fixed Assets
Investments 3,434,606
Current Assets
Debtors: amounts owing 5,690
Un-invested cash 287,310
Current Liabilities
Creditors: amounts due (24,000)
3,703,606
Capital and Reserves
Share Capital 33
Share Premium 2,699,011
Capital reserve - realised 0
Capital reserve - unrealised 0
Revenue reserve 1,004,562
3,703,606
Shares in Issue 33,000,000
Net Asset Value per share 11.22 pence

--- ENDS ---

Portfolio Details

Investments Schedule at 31st March 2013 Valuation £ Portfolio %
Synergy Pharmaceuticals Inc. 318,602 9.3%
Gilead Sciences Inc. 276,677 8.1%
Summit Corporation plc 254,061 7.4%
Celgene Corporation 220,975 6.4%
Arrowhead Research 146,728 4.3%
Pfizer Inc. 140,322 4.1%
Biogen Idec Inc. 139,516 4.1%
TrovaGene Inc. 122,493 3.6%
Nektar Therapeutics 121,507 3.5%
1,740,882 50.7%
Aggregate value of remaining holdings below 3% of total portfolio 1,693,724 49.3%
TOTAL INVESTMENTS 3,434,606 100.0%

For further information, please contact:

Port Erin Biopharma Investments Ltd Libertas Capital Corporate Finance Limited Peterhouse Capital Limited
The Company Nomad Broker
Denham Eke

+44 162 463 9396
Sandy Jamieson

+44 207 569 9650
Jon Levinson

+44 207 562 3350

This information is provided by RNS

The company news service from the London Stock Exchange

END

NAVQVLFBXZFLBBD